Rachel Humphrey, M.D.

Sporos Bioventures Logo

Dr. Humphrey has over 25 years of experience in clinical drug development and currently serves as the Chief Executive Officer of a biotech startup focused on immunotherapies.

Previous roles include Independent Director at CytomX Therapeutics, as well as Chief Medical Officer at Black Diamond Therapeutics, CytomX Therapeutics and Mirati Therapeutics, respectively. Dr. Humphrey’s career is most notable for the supervision of the development of ipilimumab (Yervoy®) at BMS and sorafenib (Nexavar®) at Bayer.

She received her B.A. from Harvard University, her M.D. from Case Western Reserve Medical School, and her training in internal medicine at The Johns Hopkins Hospital. She started her career as an oncology fellow and staff physician at the National Cancer Institute in Bethesda, MD.

Management & Scientific Founders​

Board of Directors

Scientific Advisory Board

Scroll to Top